On May 25, 2022 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that Maurice Zauderer, Ph.D., President and Chief Executive Officer, along with Elizabeth Evans, Ph.D., Chief Operating Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time (Press release, Vaccinex, MAY 25, 2022, View Source [SID1234615037]). The Company will provide an update on enrollment in phase 2 trials of its lead product in Head and Neck Cancer and in Alzheimer’s disease. Interested investors are invited to participate in one-on-one meetings, June 8 to 10.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Healthcare Conference (in-person) Details:

Please contact your Jefferies representative if you would like to schedule a one-on-one meeting during the conference, June 8 to 10, 8:00 am to 5:00 pm.

On May 25, 2022 Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, reported that John Celebi, president and chief executive officer, will present at the Jefferies Healthcare Conference, being held in New York, NY and virtually, on Wednesday, June 8, 2022 at 3:00 p.m. ET (Press release, Sensei Biotherapeutics, MAY 25, 2022, View Source [SID1234615036]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available here.

On May 25, 2022 Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, reported Cecilia McKenney, Senior Vice President and Chief Human Resources Officer (CHRO), received the "CHRO Lifetime Achievement Award" by SharedXpertise Media, publishers of HRO Today magazine and HRO Today Global (Press release, Quest Diagnostics, MAY 25, 2022, View Source [SID1234615035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Quest Diagnostics CHRO Receives "CHRO Lifetime Achievement Award"

"Cecilia is more than our Chief Human Resources Officer; she’s an empathetic leader and a fearless champion for our 50,000 colleagues," said Steve Rusckowski, Chairman, CEO and President. "She has a unique ability to connect with everyone in the organization, from a board member to our newest phlebotomist working in a patient service center. I’m grateful for what Cecilia has done for Quest Diagnostics, and for the support she has given me as a trusted advisor."

Ms. McKenney joined Quest Diagnostics in 2018 and has been an advocate for inclusion, innovation and well-being. During a challenging time when our colleagues were providing vital COVID-19 testing to the nation, Ms. McKenney championed several initiatives to support employees and their families, from financial resources to mental health programs.

"I am incredibly honored to receive this award on behalf of the entire Quest team," said Ms. McKenney. "It’s easy to bring passion to the workplace when you love the people you work with and the role your company gets to play in empowering better health for the millions we serve."

In 2014, HRO Today introduced the CHRO Awards, honoring those CHROs with the capabilities to adapt to a competitive business environment in order to deliver the insight needed for HR transformation. The CHRO of the Year award and Lifetime Achievement award and Award recognizes CHROs that help drive workforce initiatives through innovation with measurable excellence in employee engagement and retention to prove it. These CHROs are responsible for providing leadership to ensure talent acquisition and retention, business growth, and a culture that can lead in a global workforce.

On May 25, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology leader, reported that it will participate in the Bernstein 38th Annual Strategic Decisions Conference being held in New York, NY (Press release, Leidos, MAY 25, 2022, View Source [SID1234615034])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roger Krone, Chief Executive Officer, will engage in a question and answer "fireside chat" on Wednesday, June 1, 2022, at 2:30 p.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for one year afterward

On May 25, 2022 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology leader, reported that will participate in the Jefferies Virtual IT Services Summit (Press release, Leidos, MAY 25, 2022, View Source [SID1234615033]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chris Cage, Chief Financial Officer, will engage in a virtual question and answer "fireside chat" on Wednesday, June 1, 2022, at 11:00 a.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.